What is BioIntelliSense?
Based in Redwood City, California, BioIntelliSense operates at the intersection of wearable hardware and clinical analytics. The company provides a sophisticated Data-as-a-Service (DaaS) platform that captures continuous vital signs, physiological biometrics, and symptomatic events via proprietary body sensors. By moving beyond traditional episodic care, BioIntelliSense enables healthcare providers to maintain a persistent, high-fidelity view of patient health, effectively positioning itself as a critical infrastructure provider for remote patient monitoring and hospital-at-home initiatives.
How much funding has BioIntelliSense raised?
BioIntelliSense has raised a total of $70M across 2 funding rounds:
Series A
$25M
Series B
$45M
Series A (2019): $25M with participation from Jonathan Weiner and Fresenius Medical Care North America
Series B (2021): $45M led by 7wireVentures and Pendrell
Key Investors in BioIntelliSense
7wireVentures
7wire Ventures is a firm that builds and invests in early-stage digital health companies focused on creating informed and connected health consumers.
Pendrell
Pendrell Corporation invests in, acquires, and develops businesses with unique technologies that are protected by intellectual property rights.
Fresenius Medical Care North America
A major provider of kidney care products and services, focusing on integrated healthcare solutions for patients with chronic conditions.
What's next for BioIntelliSense?
Following this major strategic investment, BioIntelliSense is well-positioned to scale its enterprise-level operations and expand its clinical footprint. The company is expected to leverage this capital to enhance its algorithmic capabilities and deepen its integration with existing electronic health record systems. As the healthcare industry continues to prioritize decentralized care models, BioIntelliSense's ability to deliver continuous, medical-grade insights will likely serve as a primary driver for future market penetration and long-term commercial viability.
See full BioIntelliSense company page
